Фармакотерапия ревматоидного артрита у беременных женщин

1. Ostensen M, Fuhrer L, Mathieu R et al. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis 2004; 63: 1212–7.
2. Bowden AP, Barrett JH, Fallow W et al. Women with inflammatory polyarthritis have babies of lower birth weight. J Rheumatol 2001; 28: 355–9.
3. Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54: 899–907.
4. Mitchell K, Kaul M, Clowse MEB. The management of rheumatic diseases in pregnancy Scandinavian Journal of Rheumatology 2010; 39 (2): 99–108;
5. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000; 160: 610–9.
6. Ostensen M. Förger F. Management of RA medications in pregnant patients. Nature Reviews Rheumatology 2009; 5: 382–90.
7. De Man YA, Dolhain RJ, Van de Geijn FE et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 2008; 59 (9): 1241–8.
8. Lortscher DN, Bransington RD. Rheumatoid arthritis: treatment of newly diagnosed disease. Available at: http://www.consultantlive.com/ showArticle.jhtml?articleId5206503916 2008
9. Bermas BL. Use of immunosuppressive drugs in pregnancy and lactation. 2008. Available at http://www.utdol.com. lrc1.usuhs.edu/ utd/content/topic.do?topicKey5tx_rheum/9876
10. Piggott KD, Sorbello A, Riddle E et al.Congenital cardiac defects: a possible association of aminopterin syndrome and in utero methotrexate exposure? Pediatr Cardiol 2011; 32 (4): 518–20.
11. No authors listed. High-dose methotrexate during pregnancy: risk of malformations. Prescribe Int 2010; 19 (109): 212–3.
12. Vroom F, de Walle HE, van de Laar MA et al. Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future. Drug Saf 2006; 29 (10): 845–63.
13. Gromnica-Ihle E, Krüger K. Use of methotrexate in young patients with respect to the reproductive system. Clin Exp Rheumatol 2010; 28 (Suppl. 61): 580–4.
14. Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative Ann Rheum Dis 2009; 68 (7): 1086–93.
15. Chambers C, Johnson D, Robinson L et al. Birth Outcomes in Women Who Have Taken Leflunomide During Pregnancy. Arthritis & rheumatism May 2010; 62 (5): 1494–503.
16. Sifontis NM, Coscia LA, Constantinescu S et al. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006; 82: 1698–702.
17. Orencia® (abatacept; lyophilized powder for intravenous infusion) package insert. Bristol–Myers Squibb, 2008.
18. Levy S et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone 2008; 44: 428–30.
19. Mitchel, Clowse MEB The use of anti-TNFα medications for rheumatologic disease in pregnancy. Int J Women Health 2010; 2: 199–209.
20. Vasiliu V, Lazarescu R, Popescu A, Grigoriu E et al. Lupus erythematosus (L.E.) and pregnancy and the puerperium, in Romanian. Med Interna (Bucur) 1969; 21: 99–104.
21. Caprilli R, Gassull MA, Escher JC et al. European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006; 55 (Suppl. 1): 136–58.
22. Etminan M, Sadatsafavi M, Jafari S et al. Acetaminophen use and the risk of asthma in children and adults: a systematic review and metaanalysis. Chest 2009; 136 (5): 1316–23.
23. Nielsen GL, Sorensen HT, Larsen H et al. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 2001; 322: 266–70.
24. Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study BMJ 2003; 327 (7411): 368.
25. Bermas BL. Management of Rheumatologic Disorders During Pregnancy. Int J Clin Rheumatol 2010.
26. Cowchock FS et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992; 166 (5): 1318–23.
27. Ostensen M, von Esebeck M, Villiger PM. Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol 2007; 34 (6): 1266–9.
28. Carmichael S L et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007; 197: 585e1–e7.
29. Sperber K, Hom C, Chao CP, Shapiro D et al. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J 2009; p. 7–9.
30. Costedoat-Chalumeau N et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003; 48: 3207–11.
31. Klinger G et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001; 358: 813–4.
32. Moskovitz DN et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 2004; 99: 656–61.
33. Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratol 2002; 65: 240–61.
34. Goldstein L H et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 2007; 79: 696–701.
35. Norgard B, Pedersen L, Christensen LA & Sörensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: A Danish nationwide cohort study. Am J Gastroenterol 2007; 102: 1406–13.
36. Armenti VT et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. In: Clinical Transplants (Eds J.M.Cecka & P.I.Terasaki) 2004; 103–114 (UCLA, Los Angeles, 2004).
37. Bar Oz B, Hackman R, Einarson T & Koren G. Pregnancy outcome after CsA therapy during pregnancy: a meta-analysis. Transplantation 2001; 71: 1051–5.
38. Shaheen FAM, AI-Sulaiman MH & AI-Khader AA. Long-term nephrotoxicity after exposure to CsA in utero. Transplantation 1993; 56: 224–5.

Е.А.Ушкалова, О.Л.Романова, Т.С.Илларионова 

Кафедра общей и клинической фармакологии ГОУ ВПО РУДН Минздравсоцразвития РФ, Москва